Pleasanton and Redwood City, CA
15 September 2015
Bina Technologies, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), received top honors in the recent DREAM Mutation Calling Challenge, an open crowd-sourced competition and international effort to aggregate prediction algorithms for identifying cancer-associated mutations and rearrangements in next-generation sequencing (NGS) data. The challenge’s winning algorithms are poised to become industry standards for analyzing cancer genomes.
Bina submitted results for the detection of both somatic single nucleotide variants (SNVs) and small insertions and deletions (indels) in two categories in tumor-normal pairs. In the indel sub-challenge, the Bina team achieved an F1-score of 0.716 and took first place. In the somatic SNV sub-challenge, the Bina team ranked second, with an F1-score of 0.997. Understanding these mutations in the tumor DNA may contribute to the development of targeted therapies.
The challenge is presented by the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects, along with Sage Bionetworks and IBM-DREAM.
Bina Genomic Management Solution1 provides robust and reliable analysis of the cancer genomes along with scalable informatics infrastructure to help solve big data problems in next-generation sequencing, said Narges Bani Asadi, CEO of Bina Technologies. We pride ourselves in advancing science and contributing to the open source community. To have our detection algorithms rank at the top amongst those submitted by well-established genome institutions demonstrates our commitment to accelerating bioinformatics development in cancer research.
About Bina Technologies
Bina Technologies1 builds next-generation technologies for scalable, accurate processing and management of genomic information. Bina’s Genomic Management Solution is a comprehensive analysis platform used by clinical and translational researchers to gain insight from their genomic data sets. Bina’s Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalized medicine. Bina Technologies was acquired by Roche in December 2014. Learn more about Bina’s product, technologies, and team at www.bina.com.
1Bina products are for research use only and not for use in diagnostic procedures
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com.
For further information please contact:
Bina Technologies Media Enquiries
Erik Clausen or Trisha Rule
Chempetitive Group for Bina
Phone: +1 781.608.7091
Roche Sequencing Media Relations
VP, Marketing and Corporate Communications
Phone: +1 520.468.9145
e-mail: Jacquie Bucher